Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 161 of the 162 references it cites were found in a registry or an index.

Stem cell-based therapy for pulmonary fibrosis

Open access
Cheng, Wenzhao, Zeng, Yiming, Wang, Dachun · 2022 · Stem Cell Research & Therapy

Abstract

Pulmonary fibrosis (PF) is a chronic and relentlessly progressive interstitial lung disease in which the accumulation of fibroblasts and extracellular matrix (ECM) induces the destruction of normal alveolar structures, ultimately leading to respiratory failure. Patients with advanced PF are unable to perform physical labor and often have concomitant cough and dyspnea, which markedly impair their quality of life. However, there is a paucity of available pharmacological therapies, and to date, lung transplantation remains the only possible treatment for patients suffering from end-stage PF; moreover, the complexity of transplantation surgery and the paucity of donors greatly restrict the application of this treatment. Therefore, there is a pressing need for alternative therapeutic strategies for this complex disease. Due to their capacity for pluripotency and paracrine actions, stem cells are promising therapeutic agents for the treatment of interstitial lung disease, and an extensive body of literature supports the therapeutic efficacy of stem cells in lung fibrosis. Although stem cell transplantation may play an important role in the treatment of PF, some key issues, such as safety and therapeutic efficacy, remain to be resolved. In this review, we summarize recent preclinical and clinical studies on the stem cell-mediated regeneration of fibrotic lungs and present an analysis of concerning issues related to stem cell therapy to guide therapeutic development for this complex disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13287-022-03181-8

Cites

161 of 161 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The pathogenetic model of PF. Aging-associated changes, environmental factors and genetic susceptibility result in damage to alveolar epithelial cells. The injured epithelium secretes a plethora of mediators that induce the activation and proliferation of fibroblasts and myofibroblasts, which are resistant to apoptosis and persistently secrete ECM. The ECM also serves as a reservoir of mediators and continuously induces myofibroblast differentiation and ECM secretion in a positive feedback loop, leading to the inexorable progression of PF. By Figdraw (www.figdraw.com)
Fig. 1 The pathogenetic model of PF. Aging-associated changes, environmental factors and genetic susceptibility result in damage to alveolar epithelial cells. The injured epithelium secretes a plethora of mediators that induce the activation and proliferation of fibroblasts and myofibroblasts, which are resistant to apoptosis and persistently secrete ECM. The ECM also serves as a reservoir of mediators and continuously induces myofibroblast differentiation and ECM secretion in a positive feedback loop, leading to the inexorable progression of PF. By Figdraw (www.figdraw.com)CC BY · PubMed Central
Fig. 2 Airway epithelial cells are involved in lung repair and regeneration. The distribution of airway epithelia from the trachea, bronchi and bronchioles to alveoli is shown. Basal cells are progenitor cells of the lungs that are capable of self-renewal and differentiation into club cells, ciliated cells and goblet cells. Club cells can differentiate toward goblet cells, ciliated cells and ATII cells or toward basal cells. BASCs are located at bronchioloalveolar duct junctions (BADJs) and are involved in replenishing club cells and alveolar epithelial cells and promoting the repair and regeneration of lung tissues. ATII cells are progenitor cells of the alveolar epithelium that can self-renew and differentiate into ATI cells. By Figdraw (www.figdraw.com)
Fig. 2 Airway epithelial cells are involved in lung repair and regeneration. The distribution of airway epithelia from the trachea, bronchi and bronchioles to alveoli is shown. Basal cells are progenitor cells of the lungs that are capable of self-renewal and differentiation into club cells, ciliated cells and goblet cells. Club cells can differentiate toward goblet cells, ciliated cells and ATII cells or toward basal cells. BASCs are located at bronchioloalveolar duct junctions (BADJs) and are involved in replenishing club cells and alveolar epithelial cells and promoting the repair and regeneration of lung tissues. ATII cells are progenitor cells of the alveolar epithelium that can self-renew and differentiate into ATI cells. By Figdraw (www.figdraw.com)CC BY · PubMed Central
Fig. 3 Mechanism of MSC-based therapy for PF. MSCs home to injured lungs, where they exert immunomodulatory and antifibrotic effects via paracrine actions and activate endogenous lung stem cells to promote the regeneration of the injured lungs
Fig. 3 Mechanism of MSC-based therapy for PF. MSCs home to injured lungs, where they exert immunomodulatory and antifibrotic effects via paracrine actions and activate endogenous lung stem cells to promote the regeneration of the injured lungsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 162 references

Research works printed but not linked: 1

  1. Averyanov A, Koroleva I, Konoplyannikov M, Revkova V, Lesnyak V, Kalsin V, Danilevskaya O, Nikitin A, Sotnikova A, Kotova S, et al. First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. Stem Cells Transl Med. 2020;9(1):6–16. · DOI · Paper page

Cited by

See all 73

Metadata

Authors
Cheng, W., Zeng, Y., & Wang, D.
Affiliations
Second Affiliated Hospital of Fujian Medical University (CN)
Corresponding author
Wang, Dachun
Venue
Stem Cell Research & Therapy
Published
2022-10-04
Volume
13
Issue
1
Pages
492-492
ISSN
1757-6512 (ISSN-L)
OpenAlex
W4301396679
Cited by
65
References
162
Citations by year
2026: 10 · 2025: 23 · 2024: 22 · 2023: 9 · 2022: 1
FWCI
2.38
Type
journal article
Language
en
Open access
Licence
Locations
  • Stem Cell Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • the Quanzhou City Science & Technology Program of China: Quanzhou High-level talent team project (2020CT001)
  • the Science and Technology Department of Fujian Province, China (2020J01239)
  • the Startup Fund for Scientific Research of Fujian Medical University (2019HQ1114, BS202004)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
Keywords
pulmonary fibrosis, stem cell therapy, interstitial lung disease, lung regeneration, fibroblast accumulation, extracellular matrix, paracrine effects, stem cell transplantation, lung transplantation, stem cell safety, treatment efficacy
MeSH terms
Fibroblasts, Humans, Pulmonary Fibrosis, Quality of Life, Mesenchymal Stem Cell Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stem cell-based therapy for pulmonary fibrosis. https://app.cochat.ai/papers/10.1186/s13287-022-03181-8
The paper
Cheng, W., Zeng, Y., & Wang, D. (2022). Stem cell-based therapy for pulmonary fibrosis. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-022-03181-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.